Skye to manufacture new formulation of asthma drug

Published: 4-Aug-2006

Partner of SkyePharma, Critical Therapeutics (CTI), has submitted a new drug application to the US Food & Drug Administration (FDA) for a controlled-release formulation of the oral anti-inflammatory drug zileuton, for the treatment of asthma in adults and children over 12 years old.


Partner of SkyePharma, Critical Therapeutics (CTI), has submitted a new drug application to the US Food & Drug Administration (FDA) for a controlled-release formulation of the oral anti-inflammatory drug zileuton, for the treatment of asthma in adults and children over 12 years old.

A four times a day immediate-release version of zileuton was marketed by Abbott as Zyflo Filmtab (zileuton tablets), and SkyePharma developed the controlled-release version for Abbott, which completed phase III development.

CTI acquired the rights to zileuton and collaborated with SkyePharma on the further development of the formulation. SkyePharma will manufacture the product for CTI at its plant in Lyon, France, and receive a single-digit royalty on CTI's sales of the controlled-release version of the drug.

You may also like